Adaptive Biotechnologies Corp
ADPTQ3 2022(ADPT Q2 FY2022)Estimated10% AI
AI Revenue %
10%
AI Fair Value
$90.3M
AI Revenue (Q)
$4.4M
Total Revenue (Q)
$43.7M
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Revenue of $43.7M (single segment). Same methodology as Q1 2022 -- Immune Medicine portion ~20% of total, 50% AI attribution within IM. No segment breakout available. AI/ML is an enabling technology in the drug discovery pipeline, not the revenue-generating product itself.
Analyzed by claude-opus-4-6
Quoted Figures
Revenue $43,660K for three months ended June 30, 2022
10-Q filed 2022-08-09, Income Statement
AI Products Identified (Ring 1)
Immune Medicine TCR-Antigen Map (AI/ML-powered TCR-to-disease mapping)Adaptive Immunosequencing (research sequencing with AI/ML analysis)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
clonoSEQ diagnostic test (NGS-based)MRD Pharma testing services
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix